Robust recovery in non-COVID-19 business ensures a beat in Q1
04/05/21 -"Benefiting from strong demand for sample technology solutions and the QuantiFERON-TB test, Qiagen’s non-COVID-19 business was back in the black in Q1 21. Expectedly, COVID-19 products witnessed a ..."
Pages
60
Language
English
Published on
04/05/21
You may also be interested by these reports :
07/05/21
Coloplast (Reduce, Denmark) is, fundamentally, an attractive business (AV fundamental strength score of 9/10 vs 7.7 for AV MedTech and 5.4 for AV ...
07/05/21
Coloplast reported mixed Q2/H1 2021 numbers. Sales were up 2% on an organic basis, driven by ostomy (+4%) and urology (+3%). Adjusted EBIT was up 2% ...
07/05/21
Group’s sales momentum accelerated in Q1 driven by a strong show in Audio – both enterprise and consumers divisions reported double-digit growth. ...
07/05/21
We see a certain decoupling, of which the one related to the COVID-19 cases of FMC patients to the global trend is very positive in our view. The ...